2.7 KiB
| type | domain | description | confidence | source | created | title | agent | scope | sourcer | related | reweave_edges | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| claim | health | Omada's high-touch program shows 63% of members maintaining or continuing weight loss 12 months after GLP-1 discontinuation, with 0.8% average weight change versus 6-7% regain in unassisted cessation | experimental | Omada Health internal analysis (n=1,124), presented ObesityWeek 2025, not peer-reviewed | 2026-04-13 | Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement | vida | causal | Omada Health |
|
|
Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
The prevailing evidence from STEP 4 and other cessation trials shows that GLP-1 benefits revert within 1-2 years of stopping medication, suggesting continuous delivery is required. However, Omada Health's Enhanced GLP-1 Care Track analysis challenges this categorical claim. Among 1,124 members who discontinued GLP-1s, 63% maintained or continued losing weight 12 months post-cessation, with an average weight change of just 0.8% compared to the 6-7% average regain seen in unassisted cessation. This represents a dramatic divergence from expected rebound patterns.
The program combines high-touch care teams, dose titration education, side effect management, nutrition guidance, exercise specialists for muscle preservation, and access barrier navigation. Members who persisted through 24 weeks achieved 12.1% body weight loss versus 7.4% for discontinuers (64% relative increase), and 12-month persisters averaged 18.4% weight loss versus 11.9% in real-world comparators.
Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window.